Brief: Mabpharm Says Loss And Total Comprehensive Expense For Year Attributable RMB210.8 Mln
24/03/2023 15:08
March 24 (Reuters) - Mabpharm Ltd 2181.HK :
* LOSS AND TOTAL COMPREHENSIVE EXPENSE FOR YEAR ATTRIBUTABLE
RMB210.8 MILLION VERSUS LOSS RMB291.7 MILLION
Source text for Eikon: ID:nHKS90hhjh
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008